{
    "clinical_study": {
        "@rank": "26949", 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare 2 combination drug therapies in HIV-infected\n      patients who have never received anti-HIV treatment."
        }, 
        "brief_title": "A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label study antiretroviral-naive patients are randomized to one of two drug\n      regimens:\n\n      Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II:\n      Nelfinavir and Combivir."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  CD4 count > 50.\n\n          -  HIV RNA > 5,000.\n\n          -  No active AIDS (excluding CD4 count < 200).\n\n          -  Ability to comply with dosing schedule and protocol evaluations.\n\n        Prior Medication:\n\n        Allowed:\n\n          -  3TC or any protease inhibitor, if < 1 week of therapy.\n\n          -  Other nucleoside analogs, if < 4 weeks of therapy.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with any of the following symptoms or conditions are excluded:\n\n          -  Active AIDS (not including CD4 count < 200).\n\n          -  Malabsorption syndrome affecting drug absorption.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Enrollment in any other investigational drug protocol.\n\n        Prior Medication:\n\n        Excluded:\n\n        Non-nucleoside reverse transcriptase inhibitors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002216", 
            "org_study_id": "280C", 
            "secondary_id": [
                "UNAP 11", 
                "NZTA 4002"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "Lamivudine/Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Abacavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Amprenavir", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Nelfinavir mesylate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Lamivudine", 
                "Reverse Transcriptase Inhibitors", 
                "Abacavir", 
                "Lamivudine, zidovudine drug combination", 
                "Nelfinavir", 
                "Amprenavir", 
                "HIV Protease Inhibitors"
            ]
        }, 
        "keyword": [
            "Drug Therapy, Combination", 
            "HIV Protease Inhibitors", 
            "VX 478", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "abacavir"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pittsburgh", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "15213"
                }, 
                "name": "Anderson Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Comparison of a Four-Drug Regimen Comprised of 141W94, 1592U89, and Combivir With a Three-Drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naive HIV-Infected Patients.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002216"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 1999"
    }, 
    "geocoordinates": {
        "Anderson Clinical Research": "40.441 -79.996"
    }
}